Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101

Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis. Median survival for metastatic patients is six to nine months and survivors beyond one year are exceptional. Pancreatic cancer is resistant to conventional chemotherapy and is often diagnosed at advanced stages. However, immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa Neves, Mafalda, Giakoustidis, Alex, Stamp, Gordon, Gaya, Andy, Mudan, Satvinder
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2015
Materias:
General Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731256/
https://www.ncbi.nlm.nih.gov/pubmed/26870619
http://dx.doi.org/10.7759/cureus.435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731256/
https://www.ncbi.nlm.nih.gov/pubmed/26870619
http://dx.doi.org/10.7759/cureus.435

Ejemplares similares